Catalyst Pharmaceuticals (CPRX) announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst’s outstanding common stock between October 1, 2025, and December 31, 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25
- Catalyst Pharma Settles Patent Dispute with Lupin
- Catalyst Pharmaceuticals announces settlement of FIRDAPSE patent litigation
- Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings
- Catalyst Pharma Updates Guidelines for SCLC Treatment